Lite Strategy, Inc.
Close on Oct 19, 2026
- Market cap
- $40.13M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | – | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 17, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | – | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 19, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
| Q4 FY2023 Ended Jun 30, 2023 | Sep 26, 2023 | After market close | – | – | – |
| Q3 FY2023 Ended Mar 31, 2023 | May 11, 2023 | After market close | – | – | – |
Press releases
Announcements Lite Strategy filed with the SEC
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
Results of operations · EX-99.1 to Form 8-K
INVESTOR PRESENTATION The largest public equity vehicle built to provide accessibility to Litecoin July 2026 Nasdaq: LITS
Regulation FD disclosure · EX-99.1 to Form 8-K
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Results of operations · EX-99.1 to Form 8-K
Lite Strategy Reports Fiscal 2026 Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Lite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations
Executive or director change · Other events · EX-99.1 to Form 8-K
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy,
Material agreement · Agreement terminated · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Reports Fiscal Year End 2024 Cash Position
Results of operations · EX-99.1 to Form 8-K
Voruciclib: An Oral CDK9 Inhibitor for AML and Other Malignancies July 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
MEI Pharma to Consider Strategic Alternatives
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Voruciclib: A Selective Oral CDK9 Inhibitor Drug Candidate
Regulation FD disclosure · EX-99.1 to Form 8-K
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
Other events · EX-99.1 to Form 8-K
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
MEI Pharma Announces Results of Special Meeting of Stockholders
Agreement terminated · Shareholder vote results · Other events · EX-99.1 to Form 8-K
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
Agreement terminated · Other events · EX-99.1 to Form 8-K
601 California Street, Suite 1151
Other events · EX-99.1 to Form 8-K
MEI Pharma Responds to Anson and Cable Car
Other events · EX-99.2 to Form 8-K
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
Other events · EX-99.1 to Form 8-K
MEI Pharma Postpones Special Meeting of Shareholders
Other events · EX-99.1 to Form 8-K
MEI Pharma Reminds Shareholders to Vote FOR the
Other events · EX-99.1 to Form 8-K
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to
Other events · EX-99.1 to Form 8-K
Alliance Advisors 200 Broadacres Drive, 3rd Fl. Bloomfield, NJ 07003 PRESORT FIRST CLASS U.S. POSTAGE PAID So. HACKENSACK, NJ PERMIT
Other events · EX-99.2 to Form 8-K
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
Other events · EX-99.1 to Form 8-K
MEI Pharma Responds to Anson and Cable Car
Other events · EX-99.1 to Form 8-K
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger
Regulation FD disclosure · EX-99.1 to Form 8-K
JUNE 2023 MEI Pharma & Infinity
Regulation FD disclosure · EX-99.2 to Form 8-K
MEI Pharma Board of Directors Rejects Unsolicited Proposal
Other events · EX-99.1 to Form 8-K
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
Other events · EX-99.1 to Form 8-K
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
Results of operations · EX-99.1 to Form 8-K
SAN DIEGO – April 14, 2023 –
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising
Material agreement · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K